Last reviewed · How we verify
NCT05186207
Establishment of Special Disease Cohort for RPLand Study of Impact Mechanism of Early Embryo Development
trial testing abnormal pre-pregnancy test results that need clinical intervention in Recurrent Pregnancy Loss in 1,000 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Women's Hospital School Of Medicine Zhejiang University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 12 January 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- abnormal pre-pregnancy test results that need clinical intervention
Conditions studied
- Recurrent Pregnancy Loss — all drugs for Recurrent Pregnancy Loss →
Sponsor
Women's Hospital School Of Medicine Zhejiang University
Who can join
Adults 18 to 50, female only, with Recurrent Pregnancy Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Recurrent pregnancy loss (RPL) is a refractory disease with diverse etiologies, complex pathogenesis and limited therapeutic options. Current tests and treatments lack uniform specifications. This study is a prospective clinical cohort study which intends to screen out meaningful examination items and reliable and effective treatment. The study content includes (1) tracking the re-pregnancy information of patients with initial inevitable abortion, comparing the clinical data and examination test results between patients with single abortion and RPL, and (2) comprehensively and systematically screening the patients with initial inevitable abortion, taking those without obvious abnormalities and those with a re-pregnancy into the control group and taking those with a re-pregnancy after abnormal findings were treated into the study group, recording the pregnancy and perinatal conditions of the two groups, comparing the pregnancy outcomes of the two groups, and analyzing the risk factors for RPL. The results of this study will establish a model of maternal and newborn risk assessment for first trimester medication use and provide strong evidence-based evidence to clarify the diagnosis and treatment processes of RPL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05186207
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Pregnancy Loss
Currently open trials in the same condition.
- NCT06968026 — Effects of High-Intensity, Low-Frequency Periodic rTMS Over the Right Dorsolateral Prefrontal Cortex on Cardiac Autonomi · NA · recruiting
- NCT05725512 — Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages · Phase 4 · recruiting
- NCT06182878 — Tender Loving Care for Recurrent Pregnancy Loss · NA · recruiting
- NCT05989178 — Prospective Recurrent Pregnancy Loss Registry · recruiting
- NCT06007560 — Aerobe Cycling Training in Women With Unexplained Recurrent Pregnancy Loss · NA · active not recruiting
Other Women's Hospital School Of Medicine Zhejiang University trials
Trials by the same sponsor.
- NCT07369986 — Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer · Phase 2 · not yet recruiting
- NCT07244965 — Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervica · Phase 2 · not yet recruiting
- NCT06561308 — Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer · Phase 2 · recruiting
- NCT07106853 — Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Se · not yet recruiting
- NCT07082530 — A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05186207 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Women's Hospital School Of Medicine Zhejiang University
- Last refreshed: 21 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186207.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing